BlueWillow Biologics, based in Ann Arbor, MI, is a pioneering company at the forefront of developing next-generation mucosal vaccines. Their clinical-stage intranasal adjuvanted antigen delivery platform utilizes oil-in-water emulsion technology to elicit a balanced mucosal, cellular, and systemic immune response for robust and durable protection.
With a focus on human safety and compatibility with a broad range of antigens, BlueWillow's innovative technology has shown promising results in various clinical trials, including protection in hamsters, induction of immunity in mice, and positive interim data for vaccines against Covid-19 and anthrax. Their advancements in intranasal vaccination and immunotherapy mark them as a leader in the field of mucosal vaccine development.
Generated from the website